Drug Profile
Clindamycin controlled release
Alternative Names: C-Vad; Controlled-release clindamycin vaginal insertLatest Information Update: 24 Dec 2021
Price :
$50
*
At a glance
- Originator Controlled Therapeutics (Scotland)
- Class Antibacterials; Lincosamides; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Bacterial vaginosis
Most Recent Events
- 28 May 2004 This controlled-release clindamycin vaginal insert is available for licensing (http://www.cytokinepharmasciences.com)
- 28 May 2004 Phase-I clinical trials in Bacterial vaginosis in United Kingdom (Vaginal)